Bridge Bio has launched a new biotechnology company, QED Therapeutics focused on precision medicine for FGFR-driven diseases, where achondroplasia is included.

Meclozine, a repurposed drug for achondroplasia, is heading for phase I clinical trials. It has been shown to have restored growth rate and bone length in mice, showing promise in the treatment of achondroplasia.

TherAchon is starting a natural history study on Achondroplasia, in preparation for their next clinical trials. Learn more here.

Ascendis Pharma has dosed the first volunteers in a first-in-human phase I clinical trial with TransCon CNP. Learn more about it here.

The Brod Group, a health outcomes research, and consulting firm are currently recruiting people for an international study of pediatric achondroplasia. The authors aim to get a better understanding of the experiences and daily life of children and adolescents with achondroplasia, as well as the experiences of parents who have children with achondroplasia. Find out more about the study and how to participate here.

Developing during childhood, obesity is a common complication associated with achondroplasia, affecting more than 50% of people with this condition. Here we present a paper demonstrating that obesity in achondroplasia is markedly different from other kinds of obesity and is less prone to developing most of the complications associated with obesity. The authors have also demonstrated that treatment with soluble FGFR3 reduces weight and normalizes the metabolic disturbances associated with achondr […]